Barroso-Sousa R - Search Results

1

Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial.

Tolaney SM, Barroso-Sousa R, Keenan T, Li T, Trippa L, Vaz-Luis I, Wulf G, Spring L, Sinclair NF, Andrews C, Pittenger J, Richardson ET 3rd, Dillon D, Lin NU, Overmoyer B, Partridge AH, Van Allen E, Mittendorf EA, Winer EP, Krop IE. Tolaney SM, et al. JAMA Oncol. 2020 Oct 1;6(10):1598-1605. doi: 10.1001/jamaoncol.2020.3524. JAMA Oncol. 2020. PMID: 32880602 Free PMC article. Clinical Trial.

2

Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer.

Barroso-Sousa R, Shapiro GI, Tolaney SM. Barroso-Sousa R, et al. Breast Care (Basel). 2016 Jun;11(3):167-73. doi: 10.1159/000447284. Epub 2016 Jun 22. Breast Care (Basel). 2016. PMID: 27493615 Free PMC article. Review.

3

Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study.

Barroso-Sousa R, Paes FR, Vaz-Luis I, Batista RB, Costa RB, Losk K, Camuso K, Metzger-Filho O, Hughes ME, Bunnell CA, Golshan M, Winer EP, Lin NU. Barroso-Sousa R, et al. Breast. 2016 Dec;30:136-140. doi: 10.1016/j.breast.2016.09.013. Epub 2016 Oct 6. Breast. 2016. PMID: 27721193

4

Reply to Garcia J. et al.

Barroso-Sousa R, Lin NU. Barroso-Sousa R, et al. Breast. 2017 Aug;34:132. doi: 10.1016/j.breast.2017.05.003. Epub 2017 May 11. Breast. 2017. PMID: 28502743 No abstract available.

5

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.

Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Barroso-Sousa R, et al. JAMA Oncol. 2018 Feb 1;4(2):173-182. doi: 10.1001/jamaoncol.2017.3064. JAMA Oncol. 2018. PMID: 28973656 Free PMC article.

6

Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy.

Lee H, Hodi FS, Giobbie-Hurder A, Ott PA, Buchbinder EI, Haq R, Tolaney S, Barroso-Sousa R, Zhang K, Donahue H, Davis M, Gargano ME, Kelley KM, Carroll RS, Kaiser UB, Min L. Lee H, et al. Cancer Immunol Res. 2017 Dec;5(12):1133-1140. doi: 10.1158/2326-6066.CIR-17-0208. Epub 2017 Oct 27. Cancer Immunol Res. 2017. PMID: 29079654 Free PMC article.

7

Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management.

Barroso-Sousa R, Ott PA, Hodi FS, Kaiser UB, Tolaney SM, Min L. Barroso-Sousa R, et al. Cancer. 2018 Mar 15;124(6):1111-1121. doi: 10.1002/cncr.31200. Epub 2018 Jan 3. Cancer. 2018. PMID: 29313945 Free article. Review.

8

De-escalating treatment in the adjuvant setting in HER2-positive breast cancer.

Barroso-Sousa R, Exman P, Tolaney SM. Barroso-Sousa R, et al. Future Oncol. 2018 Apr;14(10):937-945. doi: 10.2217/fon-2017-2500. Epub 2018 Mar 28. Future Oncol. 2018. PMID: 29589471 Review.

9

Database Selection and Heterogeneity-More Details, More Credibility-Reply.

Barroso-Sousa R, Barry WT, Tolaney SM. Barroso-Sousa R, et al. JAMA Oncol. 2018 Sep 1;4(9):1295-1296. doi: 10.1001/jamaoncol.2018.1231. JAMA Oncol. 2018. PMID: 29955794 No abstract available.

10

Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.

Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L. Chang LS, et al. Endocr Rev. 2019 Feb 1;40(1):17-65. doi: 10.1210/er.2018-00006. Endocr Rev. 2019. PMID: 30184160 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

72 results

Search Page

Filters